Development, optimization and validation of an analytical method for the determination of voriconazole in plasma by high-performance liquid chromatography-ultraviolet detection: Application for comprehensive study
Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed t...
Uložené v:
| Vydané v: | Annales pharmaceutiques françaises Ročník 82; číslo 5; s. 886 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
France
01.09.2024
|
| Predmet: | |
| ISSN: | 0003-4509 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients.
Plasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5μg/mL.
The developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma.
The developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole. |
|---|---|
| AbstractList | Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients.OBJECTIVESVoriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients.Plasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5μg/mL.MATERIAL AND METHODSPlasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5μg/mL.The developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma.RESULTSThe developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma.The developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole.CONCLUSIONThe developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole. Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients. Plasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5μg/mL. The developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma. The developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole. |
| Author | Berriri, Sarra Gloulou, Olfa Safta, Fathi Mokni, Yassine Zribi, Kaouther |
| Author_xml | – sequence: 1 givenname: Sarra surname: Berriri fullname: Berriri, Sarra email: sarraberriri@hotmail.com organization: Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia. Electronic address: sarraberriri@hotmail.com – sequence: 2 givenname: Kaouther surname: Zribi fullname: Zribi, Kaouther organization: Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia – sequence: 3 givenname: Olfa surname: Gloulou fullname: Gloulou, Olfa organization: Pharmacy Department, Farhat Hached University Hospital, Sousse, Tunisia – sequence: 4 givenname: Yassine surname: Mokni fullname: Mokni, Yassine organization: Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia – sequence: 5 givenname: Fathi surname: Safta fullname: Safta, Fathi organization: Laboratory for the Chemical, Galenic and Pharmacological Development of Medicines LR12ES09, Faculty of pharmacy Monastir, avenue Ibn Sina, 5000 Monastir, Tunisia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38729517$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9Uctq3TAQ1SKlefUPQtCyi9qVLMm-7i4kbVIIZNOuLxNpHCvoFVk2OP_Z_6nzaGFgOMN5wRyTgxADEnLGWc0Zb78-1mmE7KFuWCNrpmrGmgNyxBgTlVSsPyTH0_S4obbl_CM5FLuu6RXvjsifK1zQxeQxlC80pmK9fYZiY6AQDF3AWfMG47BdtgG3FqvBUY9ljIYOMdMyIjVYMHsb_rOXmK2OAZ6jQ2oDTQ4mD_R-paN9GKuEeZN6CBqps0-zNVSPOXoo8SFDGtdqdiXDYjd5eXXXL87f6EVKbivwGvMSrqNPGUcMk12QTmU26yn5MICb8NP7PiG_f3z_dXlT3d5d_7y8uK204LxUYlCG8Z1UihupW1CiMV3XMTnIToDq-p1kbS8a1cpBsMEMAoxudGuGHQjD2uaEfH7zTTk-zTiVvbeTRucgYJynvWBK9J0Ukm_U83fqfO_R7FO2HvK6__eK5i8U0JP3 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.pharma.2024.05.002 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 38729517 |
| Genre | Validation Study Journal Article |
| GroupedDBID | 08J 08T 0R~ 457 53G 5GY AAEDT AALRI AAXUO ABJNI AFNOS AFTJW AITUG ALMA_UNASSIGNED_HOLDINGS AOOFG CGR CUY CVF EBS ECM EIF EJD F5P FDB HZ~ NPM O9- P2P RIG SEM SES 7X8 |
| ID | FETCH-LOGICAL-c311t-3f5d0184551d4c6a532d77704f473a5798406932564f30fdf3adc2c6df8a3d062 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001312044100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0003-4509 |
| IngestDate | Fri Jul 11 09:10:06 EDT 2025 Thu Apr 03 07:09:13 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | CLHP-UV Plasma Accuracy profile Optimisation Voriconazole Profile d’exactitude HPLC-UV Optimization |
| Language | English |
| License | Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c311t-3f5d0184551d4c6a532d77704f473a5798406932564f30fdf3adc2c6df8a3d062 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 38729517 |
| PQID | 3053974341 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3053974341 pubmed_primary_38729517 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-Sep 20240901 |
| PublicationDateYYYYMMDD | 2024-09-01 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-Sep |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Annales pharmaceutiques françaises |
| PublicationTitleAlternate | Ann Pharm Fr |
| PublicationYear | 2024 |
| SSID | ssj0036611 |
| Score | 2.3124244 |
| Snippet | Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 886 |
| SubjectTerms | Antifungal Agents - blood Chromatography, High Pressure Liquid - methods Drug Monitoring - methods Humans Immunocompromised Host Limit of Detection Reproducibility of Results Spectrophotometry, Ultraviolet Voriconazole - blood |
| Title | Development, optimization and validation of an analytical method for the determination of voriconazole in plasma by high-performance liquid chromatography-ultraviolet detection: Application for comprehensive study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38729517 https://www.proquest.com/docview/3053974341 |
| Volume | 82 |
| WOSCitedRecordID | wos001312044100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZtkkMvSdq8H2UCJadValvyys6lhNLQQ7PsIQl7W2Q9iGFjO_sIbP9n_k9Gsr3upRAIGB-MX6DR6NPMN98Q8k3yNEOz0VTZTFGeKk6ziGkaRClPTRhK7tu93f8Rg0EyGqXDJuA2a2iVrU_0jlqXysXIv6Nd4tLJ0en-qJ6o6xrlsqtNC42PZJ0hlHETU4xWWQSGa8-qYx7HlbEtnfP8rspLQ-MOMeIXq8DKf0CmX2yut977m9tks4GZcFXbxWfywRRfyPmw1qle9uC2K7ua9eAchp2C9XKHvPxDJepBiV7lsSnXBFloQOPM61ZMUFq8goecLH1QHOqO1IBQGBBagm7ZNu3dz06TBNH_33JiIC-gQvT-KCFbghNOplVXxwCT_GmRa1AP0xJhdSOtTReT-VR6OsHcv93XZVzCVZeI9x93VPmpeajp-eBFdHfJ3fWv25-_adP_gSoWhnPKbKwD3IEiqNNc9WXMIi2ECLjlgslYpIkr22UI2rhlgdWWSa0i1dc2kUwH_WiPrBVlYQ4ImNiGaSyU4cJBmEzGsVYS3xuFxibMHpKzdjjHOL9c0kQWplzMxt2AHpL92ibGVS0EMmYJbk3iUBy94elj8smZWk1POyHrFr2LOSUb6nmez6ZfveHieTC8eQX_Af_a |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development%2C+optimization+and+validation+of+an+analytical+method+for+the+determination+of+voriconazole+in+plasma+by+high-performance+liquid+chromatography-ultraviolet+detection%3A+Application+for+comprehensive+study&rft.jtitle=Annales+pharmaceutiques+fran%C3%A7aises&rft.au=Berriri%2C+Sarra&rft.au=Zribi%2C+Kaouther&rft.au=Gloulou%2C+Olfa&rft.au=Mokni%2C+Yassine&rft.date=2024-09-01&rft.issn=0003-4509&rft.volume=82&rft.issue=5&rft.spage=886&rft_id=info:doi/10.1016%2Fj.pharma.2024.05.002&rft_id=info%3Apmid%2F38729517&rft_id=info%3Apmid%2F38729517&rft.externalDocID=38729517 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4509&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4509&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4509&client=summon |